AbbVie Inc. (ABBV) Accounts Receivable
The a/r for AbbVie Inc. (ABBV) is $12.59 Billion with a year-over-year change of +15.29%. Accounts Receivable (A/R) represents money owed to the company by customers for goods or services delivered but not yet paid for.
ABBV A/R Chart
Current A/R
$12.59B
$12.59 Billion
Year-over-Year Change
+15.29%
vs. $10.92B prior year
Historical Data
16
Years of data available
Annual A/R History
| Year | A/R | YoY Change | % Change |
|---|---|---|---|
| 2025 | $12.59B | +$1.67B | +15.29% |
| 2024 | $10.92B | $-236.00M | -2.12% |
| 2023 | $11.15B | $-99.00M | -0.88% |
| 2022 | $11.25B | +$1.28B | +12.80% |
| 2021 | $9.98B | +$1.16B | +13.09% |
| 2020 | $8.82B | +$3.39B | +62.53% |
| 2019 | $5.43B | +$44.00M | +0.82% |
| 2018 | $5.38B | +$296.00M | +5.82% |
| 2017 | $5.09B | +$330.00M | +6.94% |
| 2016 | $4.76B | +$28.00M | +0.59% |
| 2015 | $4.73B | +$995.00M | +26.64% |
| 2014 | $3.73B | $-1.07B | -22.24% |
| 2013 | $4.80B | +$505.00M | +11.75% |
| 2012 | $4.30B | +$481.00M | +12.60% |
| 2011 | $3.82B | +$443.90M | +13.16% |
| 2010 | $3.37B | — | — |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael